Abstract
Statin is now recommended in secondary prevention after stroke or transient ischemic attacks to reduce the risk of a new stroke or major cardiovascular events. However, some issues about the extent of the benefit in some stroke patients and the risk of cerebral hemorrhage remain debated. This review shows that statins are significantly effective in decreasing the risk of further strokes despite an increase in the risk of brain hemorrhage. A significant benefit was observed in men and women, in aged patients and possibly to a greater extent in patients with carotid artery stenosis. Intensive statin therapy lowering the LDL-cholesterol beyond the cut-off value of 1.8 mmol/L (70 mg/dl) seems to be more effective than less intensive treatment and without an increased risk of side effects. Overall, statins are well tolerated. Further prospective studies should clarify whether the effect is of the same magnitude in small vessel disease and how to select the patients to reduce the risk of cerebral hemorrhage.
Keywords: Carotid stenosis, cerebral hemorrhage, cholesterol, risk, statins, stroke, therapy, treatment.
Current Vascular Pharmacology
Title:Risk and Benefit of Statins in Stroke Secondary Prevention
Volume: 11 Issue: 6
Author(s): Patrice Laloux
Affiliation:
Keywords: Carotid stenosis, cerebral hemorrhage, cholesterol, risk, statins, stroke, therapy, treatment.
Abstract: Statin is now recommended in secondary prevention after stroke or transient ischemic attacks to reduce the risk of a new stroke or major cardiovascular events. However, some issues about the extent of the benefit in some stroke patients and the risk of cerebral hemorrhage remain debated. This review shows that statins are significantly effective in decreasing the risk of further strokes despite an increase in the risk of brain hemorrhage. A significant benefit was observed in men and women, in aged patients and possibly to a greater extent in patients with carotid artery stenosis. Intensive statin therapy lowering the LDL-cholesterol beyond the cut-off value of 1.8 mmol/L (70 mg/dl) seems to be more effective than less intensive treatment and without an increased risk of side effects. Overall, statins are well tolerated. Further prospective studies should clarify whether the effect is of the same magnitude in small vessel disease and how to select the patients to reduce the risk of cerebral hemorrhage.
Export Options
About this article
Cite this article as:
Laloux Patrice, Risk and Benefit of Statins in Stroke Secondary Prevention, Current Vascular Pharmacology 2013; 11(6) . https://dx.doi.org/10.2174/157016111106140128113121
DOI https://dx.doi.org/10.2174/157016111106140128113121 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Dietary Prevention of Coronary Heart Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Mechanical Design and Control Method for SEA and VSA-based Exoskeleton Devices for Elbow Joint Rehabilitation
Neuroscience and Biomedical Engineering (Discontinued) Kinetic Measurement Techniques in the Evaluation of Lipid Metabolism
Current Drug Discovery Technologies New Trends and Advances in Oral and Maxillofacial Imaging
Current Medical Imaging Inflammatory Cardiovascular Risk Markers in Obstructive Sleep Apnoea Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Mannose Binding Lectin: A Potential Biomarker for Many Human Diseases
Current Medicinal Chemistry Drug Repurposing for the Treatment of Staphylococcal Infections
Current Pharmaceutical Design EDITORIAL: Validation Techniques for Therapeutic Molecules in Drug Discovery
Current Topics in Medicinal Chemistry Blood Coagulation and the Risk of Atherothrombosis
Current Genomics Epigenetics: New Concepts of Old Phenomena in Vascular Physiology
Current Vascular Pharmacology GRK2 Inhibition in Heart Failure: Something Old, Something New
Current Pharmaceutical Design Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Current Pharmaceutical Design Organic Antifungal Drugs and Targets of Their Action
Current Topics in Medicinal Chemistry Increasing High-Density Lipoprotein Cholesterol Through Cholesteryl Ester Transfer Protein Inhibition: A Next Step in the Fight Against Cardiovascular Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders Mechanical Circulatory Support for End-Stage Heart Failure in Repaired and Palliated Congenital Heart Disease
Current Cardiology Reviews Arterial Accelerated Aging in Dialysis Patients: The Clinical Impact of Vascular Calcification
Current Vascular Pharmacology Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design Synthesis, Physico-Chemical Properties and DFT Calculations of New 2-(4- Arylpiperazine-1-yl)-1-(3-ethylbenzofuran-2-yl)ethanols As Potential Antihypertensive Agents
Current Organic Chemistry Updated Research and Applications of Small Molecule Inhibitors of Keap1-Nrf2 Protein-Protein Interaction: a Review
Current Medicinal Chemistry